Circassia Group Plc
NIOX Group Plc engages in the design, development, and commercialization of medical devices for asthma diagnosis, monitoring, and management worldwide. It offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device and a range of consumables, including sensors, individual disposable mouthpieces, and breathing handles for the measurement of Fractional Exhaled N… Read more
Circassia Group Plc (CSSPF) - Net Assets
Latest net assets as of June 2025: $64.40 Million USD
Based on the latest financial reports, Circassia Group Plc (CSSPF) has net assets worth $64.40 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($71.00 Million) and total liabilities ($6.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $64.40 Million |
| % of Total Assets | 90.7% |
| Annual Growth Rate | 6.41% |
| 5-Year Change | -9.98% |
| 10-Year Change | -68.82% |
| Growth Volatility | 167.63 |
Circassia Group Plc - Net Assets Trend (2013–2024)
This chart illustrates how Circassia Group Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Circassia Group Plc (2013–2024)
The table below shows the annual net assets of Circassia Group Plc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $59.50 Million | -29.00% |
| 2023-12-31 | $83.80 Million | +2.32% |
| 2022-12-31 | $81.90 Million | +22.60% |
| 2021-12-31 | $66.80 Million | +1.06% |
| 2020-12-31 | $66.10 Million | -47.50% |
| 2018-12-31 | $125.90 Million | -43.99% |
| 2017-12-31 | $224.80 Million | -19.91% |
| 2016-12-31 | $280.70 Million | -31.49% |
| 2015-12-31 | $409.70 Million | +114.73% |
| 2014-12-31 | $190.80 Million | +535.05% |
| 2013-12-31 | $30.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Circassia Group Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11687900000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $43.40 Million | 72.94% |
| Other Components | $16.10 Million | 27.06% |
| Total Equity | $59.50 Million | 100.00% |
Circassia Group Plc Competitors by Market Cap
The table below lists competitors of Circassia Group Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Linzhou Heavy Machinery Group Co Ltd
SHE:002535
|
$243.93 Million |
|
Beijing Dataway Horizon Co. Ltd
SHE:301169
|
$243.98 Million |
|
W&T Offshore Inc
NYSE:WTI
|
$243.99 Million |
|
Polaris Group
TW:6550
|
$244.01 Million |
|
Runben Biotechnology Co Ltd Ordinary Shares - Class A
SHG:603193
|
$243.86 Million |
|
VIKRAM SOLAR LIMITED
NSE:VIKRAMSOLR
|
$243.72 Million |
|
Tristel PLC
PINK:TSNLF
|
$243.69 Million |
|
ADVA Optical Networking SE
PINK:ADVOF
|
$243.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Circassia Group Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 83,800,000 to 59,500,000, a change of -24,300,000 (-29.0%).
- Net income of 3,700,000 contributed positively to equity growth.
- Dividend payments of 4,200,000 reduced retained earnings.
- Share repurchases of 21,300,000 reduced equity.
- New share issuances of 100,000 increased equity.
- Other factors decreased equity by 2,600,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.70 Million | +6.22% |
| Dividends Paid | $4.20 Million | -7.06% |
| Share Repurchases | $21.30 Million | -35.8% |
| Share Issuances | $100.00K | +0.17% |
| Other Changes | $-2.60 Million | -4.37% |
| Total Change | $- | -29.00% |
Book Value vs Market Value Analysis
This analysis compares Circassia Group Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.51x to 5.31x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.17 | $0.75 | x |
| 2021-12-31 | $0.16 | $0.75 | x |
| 2022-12-31 | $0.20 | $0.75 | x |
| 2023-12-31 | $0.20 | $0.75 | x |
| 2024-12-31 | $0.14 | $0.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Circassia Group Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.22%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.85%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.15x
- Recent ROE (6.22%) is above the historical average (-26.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -66.62% | 0.00% | 0.00x | 1.27x | $-22.98 Million |
| 2014 | -18.40% | 0.00% | 0.00x | 1.05x | $-54.18 Million |
| 2015 | -12.22% | -462.04% | 0.02x | 1.20x | $-90.75 Million |
| 2016 | -48.91% | -594.37% | 0.07x | 1.19x | $-165.37 Million |
| 2017 | -44.08% | -214.04% | 0.12x | 1.79x | $-121.58 Million |
| 2018 | -93.01% | -242.44% | 0.16x | 2.44x | $-129.69 Million |
| 2020 | -50.68% | -140.17% | 0.23x | 1.56x | $-40.11 Million |
| 2021 | 5.39% | 12.90% | 0.32x | 1.29x | $-3.08 Million |
| 2022 | 19.66% | 51.44% | 0.32x | 1.20x | $7.91 Million |
| 2023 | 12.77% | 29.08% | 0.40x | 1.09x | $2.32 Million |
| 2024 | 6.22% | 8.85% | 0.61x | 1.15x | $-2.25 Million |
Industry Comparison
This section compares Circassia Group Plc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Circassia Group Plc (CSSPF) | $64.40 Million | -66.62% | 0.10x | $243.88 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |